Program
Filgrastim
Also written as “filgrastim”, “Neupogen (filgrastim)” and “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”.
Its studies are mostly in Neutropenia · Breast Neoplasms · ST Elevation Myocardial Infarction · Multiple Myeloma · Lymphoma, Non-Hodgkin, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 50 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pfizer | 50 open or running | phase 2since Nov 5, 2013 | Nov 5, 2013 | none ahead |
| Biocad | 30 open or running | phase 3since Apr 2, 2014 | Mar 30, 2012 | none ahead |
| Dong-A ST | 20 open or running | phase 3since Nov 10, 2017 | Mar 22, 2016 | none ahead |
| Novartis | 20 open or running | phase 4since May 8, 2013 | Jan 13, 2012 | none ahead |
| axaron-bioscience-ag | 10 open or running | phase 2since Aug 18, 2005 | Aug 18, 2005 | none ahead |
| Azidus Brasil | 10 open or running | phase 1since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| BioGeneric Pharma | 11 open or running | phase 1since Oct 4, 2026 | Oct 4, 2026 | Apr 7, 2027phase 1 · NCT07877467 |
| Clinique Ovo | 10 open or running | phase 3since Mar 19, 2014 | Mar 19, 2014 | none ahead |
| CSL | 10 open or running | phase 1since May 31, 2019 | May 31, 2019 | none ahead |
| Dong-A Pharmaceutical | 10 open or running | phase 1since Mar 15, 2013 | Mar 15, 2013 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 3since Mar 2, 2010 | Mar 2, 2010 | none ahead |
| hangzhou-jiuyuan-gene-engineering-co-ltd | 10 open or running | phase 2since Aug 6, 2013 | Aug 6, 2013 | none ahead |
| proteonomix-inc | 10 open or running | phase 1since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| sygnis-bioscience-gmbh-co-kg | 10 open or running | phase 2since Jun 24, 2009 | Jun 24, 2009 | none ahead |
Also a collaborator on its studies: celerion, sandoz-gmbh and numoda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Nov 2, 1999.
- Mar 15, 2013Dong-A Pharmaceutical's first study: phase 1 study in Diabetic NeuropathiesNew to Dong-A PharmaceuticalDong-A Pharmaceutical · NCT01820715 · 31 enrolled · Korea, Republic of
- May 8, 2013Phase 4 study in Neutropenia, severe chronicNovartis · NCT01859637 · 6 enrolled · Germany, Sweden
- Aug 6, 2013hangzhou-jiuyuan-gene-engineering-co-ltd's first study: phase 2 study in NeutropeniaNew to hangzhou-jiuyuan-gene-engineering-co-ltdhangzhou-jiuyuan-gene-engineering-co-ltd · NCT01918241 · 200 enrolled · China
- Nov 5, 2013Pfizer's first study: phase 2 study in Advanced Multiple MyelomaNew to PfizerPfizer · NCT01989325 · 77 enrolled · United States
- Mar 19, 2014Clinique Ovo's first study: phase 3 study in InfertilityNew to Clinique OvoClinique Ovo · NCT02149277 · 15 enrolled · Canada
- Mar 19, 2014Phase 2 study in Advanced Multiple MyelomaPfizer · NCT02092922 · 154 enrolled · United States, Belgium, Canada and more
- Apr 2, 2014Phase 3 study in NeutropeniaBiocad · NCT02104830 · 135 enrolled · Russian Federation
- Mar 22, 2016Dong-A ST's first study: phase 1 study in HealthyNew to Dong-A STDong-A ST · NCT02725086 · 56 enrolled · Korea, Republic of
- Apr 1, 2016Phase 1 study in LeukocytosisBiocad · NCT02762799 · 60 enrolled
- May 6, 20162 phase 1 studies in NeutropeniaPfizer · NCT02766647, NCT02766634
- Sep 30, 2016Phase 1 study in Healthy VolunteersPfizer · NCT02923791 · 256 enrolled · United States
- Nov 10, 2017Phase 3 study in Breast NeoplasmsDong-A ST · NCT03343145 · 143 enrolled · Indonesia
- May 31, 2019CSL's first study: phase 1 study in Hidradenitis SuppurativaNew to CSLCSL · NCT03972280 · 39 enrolled · Australia, Denmark, Germany
- Oct 4, 2026BioGeneric Pharma's first study: phase 1 study in NeutropeniaNew to BioGeneric PharmaBioGeneric Pharma · NCT07877467 · 50 planned
Ahead
- Apr 7, 2027Primary completion: phase 1 study in NeutropeniaBioGeneric Pharma · NCT07877467
TargetBeta
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule
Other programs on CSF3R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pegfilgrastimrule | Amgen | phase 4 | 52 |
| anumigilimabrule | CSL | phase 2 | 4 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07877467Neutropenia | 1 | Not yet recruiting | BioGeneric Pharma | Apr 7, 2027 | 50 |
| NCT03972280Hidradenitis Suppurativa · Australia, Denmark, Germany | 1 | Completed | CSL | Oct 4, 2022 | 39 |
| NCT03343145Breast Neoplasms · Indonesia | 3 | Completed | Dong-A ST | Jan 28, 2019 | 143 |
| NCT02923791Healthy Volunteers · United States | 1 | Completed | Pfizer | Jan 2017 | 256 |
| NCT02766647Neutropenia · United States | 1 | Completed | Pfizer | Feb 2016 | 24 |
| NCT02766634Neutropenia · United States | 1 | Completed | Pfizer | Jun 2016 | 60 |
| NCT02762799Leukocytosis | 1 | Completed | Biocad | Nov 11, 2016 | 60 |
| NCT02725086Healthy · Korea, Republic of | 1 | Completed | Dong-A ST | Apr 2016 | 56 |
| NCT02104830Neutropenia · Russian Federation | 3 | Completed | Biocad | Jun 2014 | 135 |
| NCT02149277Infertility · Canada | 3 | Terminated | Clinique Ovo | Dec 2017 | 15 |
| NCT02092922Advanced Multiple Myeloma · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Jul 2016 | 154 |
| NCT01989325Advanced Multiple Myeloma · United States | 2 | Completed | Pfizer | Feb 2016 | 77 |
| NCT01918241Neutropenia · China | 2 | UNKNOWN | hangzhou-jiuyuan-gene-engineering-co-ltd | Jan 2016 | 200 |
| NCT01859637Neutropenia, severe chronic · Germany, Sweden | 4 | Terminated | Novartis | Mar 2014 | 6 |
| NCT01820715Diabetic Neuropathies · Korea, Republic of | 1 | Completed | Dong-A Pharmaceutical | Apr 2013 | 31 |
| NCT01711073End Stage Liver Disease · United States | 1 | UNKNOWN | proteonomix-inc | Sep 2013 | 15 |
| NCT01569087Neutropenia · Russian Federation | 2 | Completed | Biocad | Jan 2013 | 60 |
| NCT01549301Healthy Subjects · Brazil | 1 | Completed | Azidus Brasil | Aug 2013 | 128 |
| NCT01519700Breast Neoplasms · Czech Republic, Hungary, Latvia and more | 3 | Completed | Novartis | Jun 2013 | 218 |
| NCT01079676Neutropenia in Breast Cancer · Brazil | 3 | Completed | Eurofarma Laboratorios | Apr 2011 | 220 |
| NCT00927836Ischemic Stroke · Austria, Belgium, Czech Republic and more | 2 | Completed | sygnis-bioscience-gmbh-co-kg | Nov 2011 | 328 |
| NCT00132470Stroke · Germany | 2 | Completed | axaron-bioscience-ag | 42 | |
| NCT00117897Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00117455Lymphoma, Non-Hodgkin | 2 | Completed | Amgen | ||
| NCT00006215Lung Neoplasms · United States | 2 | UNKNOWN | Amgen | ||
| NCT00005958Urinary Bladder Neoplasms · United States | 2 | UNKNOWN | Amgen | ||
| NCT00002126HIV Infections · United States, Canada | 2 | Completed | Amgen | 250 |
How it is read
Names in the registry
- “Filgrastim”, 11 entries
- “filgrastim”, 4 entries
- “Neupogen (filgrastim)”, 2 entries
- “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
- “Leucostim®”, 2 entries
Codes read as this program: DA3030.
Conditions, from the studies’ own filings
- Neutropenia, 7 studies
- Breast Neoplasms, 3 studies
- ST Elevation Myocardial Infarction, 2 studies
- Multiple Myeloma, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.